From plan to impact

July 4, 2018

Every three seconds someone in the world develops dementia. Dementia affects 50 million people, costing the global economy over US$1 trillion in 2018. By 2030, there will be an estimated 82 million people with dementia, placing an unprecedented strain on health systems around the world.

Spotlight

Bioarray

Bioarray is a technology-based firm, specialized in genetic analysis through cutting-edge technologies in Molecular Biology, primarily DNA microarrays/CGH and NGS, applied both to clinical and research purposes.We continuously develop our service portfolio also being flexible with client’s requirements, including customized gene panels or tailored genomic research projects requiring unparalleled bioinformatics, gene expression microarrays, RNA-seq, miRNA, methylation analysis, etc.

OTHER WHITEPAPERS
news image

The biopharmaceutical industry is leading the way in developing vaccines and treatments for COVID-19

whitePaper | April 8, 2020

The rapid spread of the novel coronavirus across the globe is a major public health threat for all, with profound health, social and economic impacts around the world. As a science-driven industry that aims to address some of the world’s biggest healthcare challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19. It has deep scientific knowledge gained from decades of experience working on developing solutions for combatting a range of infectious diseases such as MERS, SARS, Ebola and influenza.

Read More
news image

Advanced Biopharmaceutical Manufacturing: An Evolution Underway

whitePaper | June 5, 2022

The past decade has seen a significant shift in the nature of the products being manufactured and sold by the innovative biopharmaceutical (biopharma) industry. The global biopharmaceutical portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise of treatments for many orphan diseases.

Read More
news image

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Read More
news image

THE RNA PLATFORM

whitePaper | May 26, 2022

Exploring biomarkers with the new central dogma. It can be a daunting decision for scientists to know when to focus on DNA, messenger RNA (mRNA), non-coding RNA (ncRNA) or protein biomarkers for routine clinical use, with each exhibiting its own strengths and limitations

Read More
news image

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

whitePaper | September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).

Read More
news image

Becoming a life sciences superpower

whitePaper | September 1, 2021

This report advocates for increased, long-term public investment in research and innovation, particularly in the life sciences sector, to accelerate the UK on its trajectory as a global leader in the field. This report sets out recommendations ahead of the Comprehensive Spending Review for policymakers to support innovative businesses, achieve the Prime Minister’s aim of becoming a life sciences superpower, and ultimately, deliver health benefits for Britain – and the world – for generations to come.

Read More

Spotlight

Bioarray

Bioarray is a technology-based firm, specialized in genetic analysis through cutting-edge technologies in Molecular Biology, primarily DNA microarrays/CGH and NGS, applied both to clinical and research purposes.We continuously develop our service portfolio also being flexible with client’s requirements, including customized gene panels or tailored genomic research projects requiring unparalleled bioinformatics, gene expression microarrays, RNA-seq, miRNA, methylation analysis, etc.

Events